Aurobino gains Novartis's U.S. dermatology and general U.S. oral solids portfolio

Novartis AG (NYSE:NVS; SIX:NOVN) said it will sell its Sandoz U.S. dermatology business and generic oral solids portfolio to Aurobindo Pharma Ltd. (NSE:AUROPHARMA; BSE:524804) for $900 million in cash. Novartis is also eligible for $100 million in milestones. ...